Patents Assigned to Amgen
  • CARRIER IMMUNOGLOBULINS
    Publication number: 20170190793
    Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 6, 2017
    Applicant: AMGEN INC.
    Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
  • Pharmaceutical compositions with resistance to soluble CEA
    Patent number: 9695250
    Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: July 4, 2017
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Ralf Lutterbüse, Petra Fluhr, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
  • ANTIBODIES TO OPGL
    Publication number: 20170183417
    Abstract: Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
    Type: Application
    Filed: September 2, 2016
    Publication date: June 29, 2017
    Applicant: AMGEN INC.
    Inventors: William J. BOYLE, Francis H. MARTIN, Jose R. CORVALAN, C. Geoffrey DAVIS
  • Cholesteryl Ester Transfer Protein (CETP) Inhibitor and Pharmaceutical Compositions Comprising Said Inhibitor for Use in the Treatment or Prevention of Cardiovascular Diseases
    Publication number: 20170182048
    Abstract: The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor: (hereinafter referred to as Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.
    Type: Application
    Filed: February 5, 2014
    Publication date: June 29, 2017
    Applicant: AMGEN INC.
    Inventors: John FORD, Patrick ROUND, John KASTELEIN, Atsuhiro KAWAGUCHI, Koichi TOMIYASU, Kozo OKA
  • Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
    Patent number: 9688760
    Abstract: The present invention relates in essence to use of a compound, which decreases or inhibits the binding of mammalian T-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by a therapy which comprises re-directing of T-cells against target cells in a patient. Such a therapy includes, but is not limited to, treatment with an antibody comprising a CD3 binding domain, such as a CD20×CD3 or a CD19×CD3 bispecific single chain antibody, e.g., blinatumomab (MT-103). Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of T-cells against target cells are also contemplated, as are methods of identifying a compound for administration in the methods of prophylaxis, amelioration and/or treatment.
    Type: Grant
    Filed: February 8, 2014
    Date of Patent: June 27, 2017
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Dirk Nagorsen, Juergen Scheele, Gerhard Zugmaier, Matthias Klinger, Patrick Hoffmann, Virginie Naegele, Elaine-Pashupati Dopfer
  • Ferroportin antibodies and methods of use
    Patent number: 9688759
    Abstract: Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: June 27, 2017
    Assignee: Amgen, Inc.
    Inventors: Tara Arvedson, Gregory Dyas, James B. Rottman, Barbra Sasu, Xiao-juan Bi, Grace Ki Jeong Lee, Jackie Z. Sheng
  • Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor
    Patent number: 9688756
    Abstract: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment, that is, little or no binding activity at a physiologic pH. Also described are variant Fc-polypeptides that comprise these variant Fc-fragments. Further described are methods of making and identifying such Fc-fragments and methods for making and using such Fc-polypeptides.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 27, 2017
    Assignee: AMGEN INC.
    Inventors: Jeonghoon Sun, Seog Joon Han, Susie M Harris, Randal R Ketchem, Ji Lu, Mark L Michaels, Marc W Retter, Mei-Mei Tsai
  • METHODS OF TREATING NAIL AND SCALP PSORIASIS
    Publication number: 20170174772
    Abstract: The present invention relates to a therapeutic agent for nail and scalp psoriasis comprising an IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as monoclonal antibodies that bind IL-17RA, and method of using the same.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Applicant: Kirin-Amgen, Inc.
    Inventors: Ajay Nirula, Hidemi Nakagawa, Kenji Ohtaki, Hiroki Matsudo, Paul Klekotka, Gregory Kricorian
  • PROTEIN BIOMARKER AND USES THEREOF
    Publication number: 20170166654
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co. Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • NUCLEIC ACID BIOMARKER AND USE THEREOF
    Publication number: 20170166973
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, AMGEN, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
  • BCMA ANTIGEN BINDING PROTEINS
    Publication number: 20170165373
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 15, 2017
    Applicant: Amgen Inc.
    Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
  • OVEREXPRESSION OF N-GLYCOSYLATION PATHWAY REGULATORS TO MODULATE GLYCOSYLATION OF RECOMBINANT PROTEINS
    Publication number: 20170166942
    Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.
    Type: Application
    Filed: December 11, 2014
    Publication date: June 15, 2017
    Applicant: AMGEN INC.
    Inventors: Shivani GUPTA, Sohye KANG
  • Human PAC1 antibodies
    Patent number: 9676851
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignee: AMGEN INC.
    Inventors: Cen Xu, Agnes Eva Hamburger
  • PROCESS CONTROL SYSTEMS AND METHODS FOR USE WITH FILTERS AND FILTRATION PROCESSES
    Publication number: 20170157566
    Abstract: Systems and methods used to control tangential flow filtration are provided, including control systems and methods for use with connected systems with upstream processing units, such as chromatography processing units, in fluid communication with a tangential flow filtration processing unit. Also included are control systems and methods for performing continuous concentration using single-pass tangential flow filtration with permeate flow control.
    Type: Application
    Filed: May 13, 2015
    Publication date: June 8, 2017
    Applicant: AMGEN INC.
    Inventors: Eva Gefroh, Randolph W. Schweickart, Krista Petty, Gregory Frank, Christine Salstrom Terpsma, Arthur C. Hewig, III, Joseph Edward Shultz
  • COMPOSITIONS OF PEGYLATED SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS AND METHODS OF PREPARING
    Publication number: 20170151338
    Abstract: The present invention provides for improved compositions comprising a PEGsTNF-R1 which, in addition to having useful higher concentrations, demonstrate decreased viscosity (<400 cP) and improved stability.
    Type: Application
    Filed: February 7, 2017
    Publication date: June 1, 2017
    Applicant: AMGEN INC.
    Inventors: Bruce Authur Kerwin, Byeong S. Chang, Lei Shi
  • Glycine transporter-1 inhibitors
    Patent number: 9663476
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: May 30, 2017
    Assignee: AMGEN INC.
    Inventors: Stephen A. Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
    Patent number: 9663508
    Abstract: The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 30, 2017
    Assignee: Amgen Inc.
    Inventors: Howard Bregman, Nagasree Chakka, Erin F. Dimauro, Hua Gao, Hakan Gunaydin, Hongbing Huang, Philip R. Olivieri, Laurie Schenkel, Matthew Weiss
  • Vial adapter and system
    Patent number: 9662271
    Abstract: A vial adapter includes a base having first and second opposing sides, a spike depending from the first side of the base, the spike having a spike passageway, and a connector disposed on the second side of the base, the connector having a connector passageway that is in fluid communication with the spike passageway. The vial adapter may be combined with a vial.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: May 30, 2017
    Assignee: AMGEN INC.
    Inventors: Mark Dominis Holt, Alexander Stuart Cairns
  • Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer
    Publication number: 20170144971
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 25, 2017
    Applicant: AMGEN INC.
    Inventors: Michael D. BARTBERGER, Ana GONZALEZ BUENROSTRO, Hilary Plake BECK, Xiaoqi CHEN, Richard Victor CONNORS, Jeffrey DEIGNAN, Jason A. DUQUETTE, John EKSTEROWICZ, Benjamin FISHER, Brian M. FOX, Jiasheng FU, Zice FU, Felix GONZALEZ LOPEZ DE TURISO, Michael W. GRIBBLE, Jr., Darin J. GUSTIN, Julie A. HEATH, Xin HUANG, XianYun JIAO, Michael G. JOHNSON, Frank KAYSER, David John KOPECKY, SuJen LAI, Yihong LI, Zhihong LI, Jiwen LIU, Jonathan D. LOW, Brian S. LUCAS, Zhihua MA, Lawrence R. MCGEE, Joel MCINTOSH, Dustin L. MCMINN, Julio C. MEDINA, Jeffrey Thomas MIHALIC, Steven H. OLSON, Yosup REW, Phillip M. ROVETO, Daqing SUN, Xiaodong WANG, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU
  • Triazole agonists of the APJ receptor
    Patent number: 9656997
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: May 23, 2017
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, Julie Anne Heath, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, David John Kopecky, Su-Jen Lai, Zhihua Ma, Lawrence R. McGee, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Kevin Yang, Mikkel V. Debenedetto, Robert P. Farrell, Simon J. Hedley, Ted C. Judd, Frank Kayser